Novartis and Gilead Sciences are positioned well for economic downturns. Novartis offers a diverse portfolio with over 20 branded drugs, generating consistent revenue and earnings. Gilead leads the HIV market with treatments like Biktarvy and has a strong dividend growth record. Both companies are solid investments in uncertain markets.

Read more at Yahoo Finance: 2 Surefire Dividend Stocks to Buy for the Long Haul